GlassScriptPhysician profile
David A Slosky
NPI 1386731404
$8,069.07
in general payments reported to CMS, 2019-2025
20 companies · $5,015 in 2025
The $5,015 reported for 2025 was more than what 92% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $752 · 2020: $6.10 · 2021: $137 · 2022: $369 · 2023: $35.89 · 2024: $1,754 · 2025: $5,015.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,000 · Travel and Lodging: $1,586 · Food and Beverage: $1,219.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,000.00 |
| Travel and Lodging | $1,586.18 |
| Food and Beverage | $1,218.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $5,997.29 | 2019-2025 | |
| Angiodynamics, INC. | $250.00 | 2019 | |
| Janssen Pharmaceuticals, INC | $223.96 | 2019-2021 | |
| Amgen INC. | $221.02 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $218.35 | 2025 | Keytruda, Keytruda Qlex, Welireg |
| Janssen Biotech, INC. | $155.18 | 2025 | Rybrevant, Carvykti |
| Kite Pharma, INC. | $146.83 | 2025 | Yescarta |
| Immunocore Limited | $127.46 | 2025 | Kimmtrak |
| Stemline Therapeutics INC. | $119.16 | 2025 | Orserdu |
| Heartflow, INC. | $118.69 | 2022 | |
| Akcea Therapeutics, INC. | $104.10 | 2019 | |
| Alnylam Pharmaceuticals INC. | $95.01 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $89.26 | 2025 | Tagrisso |
| Taiho Oncology, INC. | $54.26 | 2025 | |
| Novartis Pharmaceuticals Corporation | $33.53 | 2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $29.78 | 2025 | Libtayo |
| Coala Life INC | $27.22 | 2023 | Coala Heart Monitor |
| Astellas Pharma US INC | $24.38 | 2025 | Xtandi |
| Genzyme Corporation | $17.06 | 2025 | |
| Lexicon Pharmaceuticals, INC. | $16.53 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Slosky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.